ECOG Protocols Active as of 08/20/08

Click on the protocol number to view the NCI's PDQ description of the protocol.


GENITOURINARY COMMITTEE


ProtocolTitle
90202 A Randomized, Double Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
Activation Date: 09-feb-2004
C90203 A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Activation Date: 15-dec-2006
E2804 The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
Activation Date: 14-sep-2007
E2805 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Activation Date: 24-apr-2006
E3803 A Phase II Study of a Weekly Schedule of BMS-247550 for Patients with Hormone Refractory Prostate Cancer
Activation Date: 16-sep-2004
ECOG Participants(requires Adobe Acrobat)
E3805 CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Activation Date: 28-jul-2006
E4805 A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma
Activation Date: 21-dec-2007
ECOG Participants(requires Adobe Acrobat)
E5805 Phase II Trial of E7389 (Halichondrin B Analog), in Patients with Metastatic Hormone Refractory Prostate Cancer
Activation Date: 29-nov-2006 Suspended: 25-jun-2008
ECOG Participants(requires Adobe Acrobat)
JPR11 A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer (START) (Limited institution participation)
Activation Date: 11-jun-2008
R0524 A PHASE I/II TRIAL OF A COMBINATION OF PACLITAXEL AND TRASTUZUMAB WITH DAILY IRRADIATION OR PACLITAXEL ALONE WITH DAILY IRRADIATION FOLLOWING TRANSURETHRAL SURGERY FOR NON-CYSTECTOMY CANDIDATES WITH MUSCLE-INVASIVE BLADDER CANCER
Activation Date: 09-jan-2007
S0421 Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Activation Date: 22-aug-2006
S9346 Phase III Study of Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer
Activation Date: 27-mar-1996

Back


How to contact ECOG

All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 08/20/08